title: Repeated rituximab-induced serum sickness with anaphylaxis.
abstract: We describe a patient who developed repeated rituximab-induced serum sickness (RISS) followed by anaphylaxis soon after the third administration of rituximab at relapse. A 65-year-old woman with Sjögren's syndrome and relapsed mucosal associated lymphoma tissue (MALT) lymphoma of the lung underwent rituximab monotherapy (375 mg/m(2)/week). Several days after the second exposure to rituximab, she developed a rash, fever, and arthralgia. These symptoms showed relief, but a severe anaphylactic reaction occurred when she was treated with rituximab for the third time. Although a rare complication in patients with lymphoma, clinicians should be aware of RISS symptoms and avoid repeatedly administering rituximab to such patients.
authors.affiliation: Department of Hematology, National Hospital Organization Nishigunma Hospital.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Isoda
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Naru
authors.initials: N
authors.lastname: Sato
authors.forename: Yuri
authors.initials: Y
authors.lastname: Miyazawa
authors.forename: Morio
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Morio
authors.initials: M
authors.lastname: Sawamura
mesh_terms: D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy; D000069283:Rituximab / Q000009:adverse effects* / Q000627:therapeutic use; D012713:Serum Sickness / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab